Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

"Eisai's entry into Russia is fully aligned with the company's wider strategy of establishing a solid foundation in the EMEA region. We currently have a number of products in the final stages of ...

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

Eisai will begin communicating with PCPs in ... partnership opportunities and in-house manufacturing of its major products. The company’s three pillars for medium to long-term growth lay in ...

Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

with both Biogen and Eisai responsible for the joint commercialisation of the product. Eisai holds final decision-making authority. Within the EU, excluding the Nordic nations, the companies will ...